Immunome INC Form 4 insider transactions

Jean Jacques Bienaime, a director at Immunome Inc., recently purchased 7,000 shares of the company's common stock at an average price of $13.944 per share.

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, exercised stock options and sold shares to cover the transaction.

Immunome Inc. CEO Clay B. Siegall reports the acquisition of 800,000 stock options in a Form 4 filing with the SEC.

Sandra G. Stoneman, Chief Legal Officer & GC of Immunome Inc., acquired 210,000 stock options on August 9, 2024.

Kinney Horn, Chief Business Officer of Immunome Inc., acquired stock options for 130,000 shares on August 9, 2024.

Bruce Turner, Chief Strategy Officer of Immunome Inc., reports the acquisition of 110,000 stock options.

Immunome Inc.'s EVP, Operations & CFO, Max Rosett, acquired 190,000 stock options on August 9, 2024, at an exercise price of $12.92.

Robert Lechleider, Chief Medical Officer of Immunome Inc., reports the acquisition of 200,000 stock options.

Immunome Inc.'s Chief Scientific Officer, Jack Higgins, acquired 190,000 stock options on August 9, 2024, at an exercise price of $12.92.

Philip Tsai, Chief Technology Officer of Immunome Inc., reports the acquisition of stock options.

Director James P. Boylan acquired stock options in Immunome Inc. on June 13, 2024, but disclaims beneficial ownership due to an agreement with Enavate Sciences, LP.

Director Carol Schafer acquired stock options in Immunome Inc. on June 13, 2024.

Director Sandra M. Swain reports the acquisition of stock options in Immunome Inc.

Director Philip Wagenheim of Immunome Inc. reports the acquisition of stock options.

Director Jean Jacques Bienaime acquired 11,333 stock options in Immunome Inc. on June 13, 2024.

Director Isaac Barchas acquired 11,333 stock options in Immunome Inc. on June 13, 2024.

Director Jean Jacques Bienaime reported the acquisition of 2,000 shares of Immunome Inc. common stock on May 21, 2024.

Clay B. Siegall, President and CEO of Immunome Inc., recently acquired additional shares of the company's common stock through open market purchases.

EVP, Operations & CFO of Immunome, Max Rosett, reports the acquisition of stock options.

Director Sandra M. Swain reports the acquisition of stock options in Immunome Inc. on April 25, 2024.